Capricor Therap (CAPR)

$7.36 -0.61 (-7.65%)
Market Cap 336.48M
Revenue (ttm) 22.27M
Net Income (ttm) -40.47M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -181.72%
Debt to Equity Ratio 0.00
Volume 1,664,300
Avg Vol 1,546,428
Day's Range N/A - N/A
Shares Out 45.72M
Stochastic %K 65%
Beta 0.68
Analysts Strong Sell
Price Target $20.60

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 727 1755
Address:
10865 Road to the Cure, Suite 150, San Diego, United States
WBinthehouse
WBinthehouse Oct. 5 at 11:33 PM
$CAPR Don’t let Fud take your cheap shares. Add down here! “p = 0.0044 In the HOPE-2 phase 2 trial by Capricor Therapeutics (CAPR), CAP-1002 showed a statistically significant improvement in left ventricular ejection fraction (LVEF) compared to placebo. The CAP-1002 group had a mean increase of +0.1 percentage points, while the placebo group had a mean decrease of -3.9 percentage points. This resulted in an effect size of +4.0 percentage points (or about 7% of baseline LVEF), with a difference in percentile ranks of 45.7 (95% CI: 19.1–72.2). The analysis used a non-parametric rank-based test, yielding p = 0.0044, which remained significant even after Bonferroni adjustment for multiple comparisons.” lol.004 absurd. Bet the farm.
0 · Reply
viber7
viber7 Oct. 5 at 5:36 PM
$CAPR LIAR. FDA recognizes LVEF as a criterion for cardiac status, although LVEF may still be only a secondary endpoint for the BLA. If LVEF is positive, cardio will be approved. You are a triple flunky in medicine, English, logic.
3 · Reply
PacoPablo
PacoPablo Oct. 5 at 5:20 PM
$CAPR I've been around long enough to know that shorts, currently over 12 million, determine the price. I'm under no illusions about that. We would need daily volumes well above 5 million for anything to change here. And it will be a good two months before the data from P3 is available. Only then will it be decided whether the journey continues. For my part, I am already thinking about success, otherwise I would no longer be on board. Although I know, from experience, that a lot can still happen in the meantime.
1 · Reply
WBinthehouse
WBinthehouse Oct. 5 at 5:14 PM
$CAPR weed out all the noise. The drug works. Positive Topline data readout coming out soon. 'We have designed a cellular product for #Duchenne muscular dystrophy, called Deramiocel, and we have had positive results in at least two clinical trials” Dr. Marbán is founding director of @SmidtHeart and his lab intensively studies cardiac. Third clinical trial is going to be a charm. Don’t let additional samples requested by the FDA we know as stat sig from the previous trials changed by FUDS as we wait for results they claim doesn’t work make you miss out on an opportunity of a lifetime. Go big or go home!
1 · Reply
RandyRandyRandy
RandyRandyRandy Oct. 5 at 3:40 PM
$CAPR If the FDA says NO for a SECOND time. How low will this go??
1 · Reply
ripztrip
ripztrip Oct. 5 at 3:37 PM
$CAPR
0 · Reply
Semafore
Semafore Oct. 5 at 3:16 PM
$CAPR HODL! You ready shorts? We know you are at the end of the line.
1 · Reply
BioResearcher
BioResearcher Oct. 5 at 1:00 PM
$CAPR Oops, sorry wrong board.
0 · Reply
BioResearcher
BioResearcher Oct. 5 at 12:59 PM
$CAPR Analyst think it will rocket soon !!! $81 is the target !!!
0 · Reply
Semafore
Semafore Oct. 5 at 12:42 PM
$CAPR
0 · Reply
Latest News on CAPR
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Oct 3, 2025, 10:45 AM EDT - 2 days ago

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 3:51 PM EDT - 6 days ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Sep 29, 2025, 9:08 AM EDT - 6 days ago

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 11:07 AM EDT - 10 days ago

Capricor Therapeutics, Inc. - Special Call

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 25, 2025, 7:15 AM EDT - 10 days ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 13, 2025, 11:35 AM EDT - 22 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Sep 9, 2025, 9:20 AM EDT - 26 days ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 28, 2025, 7:05 PM EDT - 5 weeks ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 6 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 18, 2025, 11:35 AM EDT - 6 weeks ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 8, 2025, 8:30 AM EDT - 2 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Aug 6, 2025, 9:00 AM EDT - 2 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 31, 2025, 8:45 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 4:27 PM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

Jul 30, 2025, 11:07 AM EDT - 2 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 17, 2025, 4:46 PM EDT - 2 months ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 16, 2025, 7:55 PM EDT - 2 months ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 4:14 PM EDT - 2 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

Jul 14, 2025, 7:43 AM EDT - 2 months ago

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Jul 11, 2025, 4:53 PM EDT - 3 months ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Jul 11, 2025, 9:03 AM EDT - 3 months ago

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jul 11, 2025, 8:20 AM EDT - 3 months ago

Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

FEIM

US FDA declines to approve Capricor's muscle disorder therapy

Jul 11, 2025, 6:36 AM EDT - 3 months ago

US FDA declines to approve Capricor's muscle disorder therapy

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Jul 11, 2025, 6:30 AM EDT - 3 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

Jun 24, 2025, 2:51 PM EDT - 3 months ago

FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Jun 24, 2025, 9:16 AM EDT - 3 months ago

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Why Is Capricor Therapeutics Stock Trading Lower On Monday?

Jun 23, 2025, 12:46 PM EDT - 3 months ago

Why Is Capricor Therapeutics Stock Trading Lower On Monday?

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Jun 20, 2025, 3:11 PM EDT - 3 months ago

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

Jun 20, 2025, 9:25 AM EDT - 3 months ago

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

WBinthehouse
WBinthehouse Oct. 5 at 11:33 PM
$CAPR Don’t let Fud take your cheap shares. Add down here! “p = 0.0044 In the HOPE-2 phase 2 trial by Capricor Therapeutics (CAPR), CAP-1002 showed a statistically significant improvement in left ventricular ejection fraction (LVEF) compared to placebo. The CAP-1002 group had a mean increase of +0.1 percentage points, while the placebo group had a mean decrease of -3.9 percentage points. This resulted in an effect size of +4.0 percentage points (or about 7% of baseline LVEF), with a difference in percentile ranks of 45.7 (95% CI: 19.1–72.2). The analysis used a non-parametric rank-based test, yielding p = 0.0044, which remained significant even after Bonferroni adjustment for multiple comparisons.” lol.004 absurd. Bet the farm.
0 · Reply
viber7
viber7 Oct. 5 at 5:36 PM
$CAPR LIAR. FDA recognizes LVEF as a criterion for cardiac status, although LVEF may still be only a secondary endpoint for the BLA. If LVEF is positive, cardio will be approved. You are a triple flunky in medicine, English, logic.
3 · Reply
PacoPablo
PacoPablo Oct. 5 at 5:20 PM
$CAPR I've been around long enough to know that shorts, currently over 12 million, determine the price. I'm under no illusions about that. We would need daily volumes well above 5 million for anything to change here. And it will be a good two months before the data from P3 is available. Only then will it be decided whether the journey continues. For my part, I am already thinking about success, otherwise I would no longer be on board. Although I know, from experience, that a lot can still happen in the meantime.
1 · Reply
WBinthehouse
WBinthehouse Oct. 5 at 5:14 PM
$CAPR weed out all the noise. The drug works. Positive Topline data readout coming out soon. 'We have designed a cellular product for #Duchenne muscular dystrophy, called Deramiocel, and we have had positive results in at least two clinical trials” Dr. Marbán is founding director of @SmidtHeart and his lab intensively studies cardiac. Third clinical trial is going to be a charm. Don’t let additional samples requested by the FDA we know as stat sig from the previous trials changed by FUDS as we wait for results they claim doesn’t work make you miss out on an opportunity of a lifetime. Go big or go home!
1 · Reply
RandyRandyRandy
RandyRandyRandy Oct. 5 at 3:40 PM
$CAPR If the FDA says NO for a SECOND time. How low will this go??
1 · Reply
ripztrip
ripztrip Oct. 5 at 3:37 PM
$CAPR
0 · Reply
Semafore
Semafore Oct. 5 at 3:16 PM
$CAPR HODL! You ready shorts? We know you are at the end of the line.
1 · Reply
BioResearcher
BioResearcher Oct. 5 at 1:00 PM
$CAPR Oops, sorry wrong board.
0 · Reply
BioResearcher
BioResearcher Oct. 5 at 12:59 PM
$CAPR Analyst think it will rocket soon !!! $81 is the target !!!
0 · Reply
Semafore
Semafore Oct. 5 at 12:42 PM
$CAPR
0 · Reply
Semafore
Semafore Oct. 5 at 12:42 PM
$CAPR
1 · Reply
ripztrip
ripztrip Oct. 5 at 12:24 PM
$CAPR Exciting two months ahead! Shorts are getting nervous, watch the level of their posts skyrocket the next few weeks. They are DESPERATE to keep this down for as long as they can. They made a killing over the last 4 months.
1 · Reply
ripztrip
ripztrip Oct. 5 at 12:23 PM
$CAPR
0 · Reply
ripztrip
ripztrip Oct. 5 at 12:23 PM
$CAPR
0 · Reply
hegdaom
hegdaom Oct. 5 at 11:59 AM
$CAPR
1 · Reply
hegdaom
hegdaom Oct. 5 at 11:59 AM
$CAPR
0 · Reply
Machman1
Machman1 Oct. 5 at 11:20 AM
$CAPR I believe another video documentary is being made with some kids in the trial. They could be still trying to convince FDA. Not sure how to interpret that
1 · Reply
Atmwireless
Atmwireless Oct. 5 at 6:13 AM
$CAPR wonder what that’s about
6 · Reply
hegdaom
hegdaom Oct. 5 at 3:57 AM
$CAPR
0 · Reply
hegdaom
hegdaom Oct. 5 at 3:43 AM
$CAPR
0 · Reply
hegdaom
hegdaom Oct. 5 at 3:42 AM
$CAPR
0 · Reply
hegdaom
hegdaom Oct. 5 at 3:42 AM
$CAPR
0 · Reply